Sangamo BioSciences Inc. (NASDAQ:SGMO) reached a new 52-week low on Thursday . The company traded as low as $4.35 and last traded at $4.37, with a volume of 310,342 shares trading hands. The stock had previously closed at $4.41.

A number of equities research analysts recently weighed in on SGMO shares. Wells Fargo & Co. started coverage on Sangamo BioSciences in a report on Tuesday, May 3rd. They set a “buy” rating for the company. Wedbush reaffirmed an “outperform” rating and set a $30.00 price target on shares of Sangamo BioSciences in a report on Friday, May 6th. Jefferies Group reissued a “buy” rating and issued a $14.00 target price on shares of Sangamo BioSciences in a research note on Thursday, June 9th. Zacks Investment Research cut Sangamo BioSciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 5th. Finally, Janney Montgomery Scott cut Sangamo BioSciences from a “buy” rating to a “neutral” rating and lowered their target price for the company from $15.00 to $8.00 in a research note on Thursday, August 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $15.58.

The company’s 50 day moving average is $5.61 and its 200-day moving average is $5.96. The stock’s market capitalization is $310.01 million.

Sangamo BioSciences (NASDAQ:SGMO) last issued its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.14. During the same period in the previous year, the company posted ($0.17) EPS. The firm earned $3.70 million during the quarter, compared to the consensus estimate of $5.38 million. The firm’s revenue for the quarter was down 56.0% on a year-over-year basis. Equities analysts predict that Sangamo BioSciences Inc. will post ($1.11) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Sangamo BioSciences stock. Royce & Associates LLC increased its stake in shares of Sangamo BioSciences Inc. (NASDAQ:SGMO) by 47.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 312,100 shares of the biopharmaceutical company’s stock after buying an additional 100,000 shares during the period. Royce & Associates LLC owned about 0.45% of Sangamo BioSciences worth $2,849,000 as of its most recent SEC filing.

Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.